CBX

 Innovent has initiated a phase 1 study (NCT06349408 ) of IBI3001, a bispecific ADC that targets B7-H3 and EGFR, in patients with solid tumors. Additionally, Innovent is conducting a phase 1 trial ( NCT05774873 ) of IBI344, a bispecific antibody that also targets B7-H3 and EGFR. Schematic overview of crosstalk between the EGFR signaling and the B7/CD28 family Recent research has suggested that the overexpression of novel B7/CD28 family proteins, including B7-H3 may be linked to EGFR signaling and could potentially lead to resistance to EGFR-targeted treatments by promoting an immune-depressed environment within the tumor microenvironment. IBI3001 According to the statement by Innovent, IBI3001 is a  site-specifically glycan-conjugated ADC that consists of a topoisomerase I inhibitor  with  multiple anti-tumor mechanisms of action : (1) enhanced EGFR signaling blockade; (2) EGFR- and B7-H3-aided payload internalization and cytotoxicity; and (3) potent bystander killing effects of ADC.